# Trade Mark Journal No.2026/002 9 January 2026

## WO0000001892220 (5,42)

Office of origin: United States of America

Date of International Registration:17 November 2025
Date of designation in the UK: 17 November 2025

Class 5
  Pharmaceutical preparations for the treatment of neuropsychiatric conditions, namely, autism spectrum disorder and its symptoms.
Class 42
  Pharmaceutical research in the field of treatments for neuropsychiatric conditions, namely, autism spectrum disorder and its symptoms.

Coreterra Therapeutics, Inc.

Representative: Lynn E. Rzonca Ballard Spahr LLP, 1735 Market Street, 51st Floor, Philadelphia PA 19103, UNITED STATES OF AMERICA